| __timestamp | ADMA Biologics, Inc. | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 26684000 |
| Thursday, January 1, 2015 | 6745968 | 29829000 |
| Friday, January 1, 2016 | 8494742 | 39578000 |
| Sunday, January 1, 2017 | 18092835 | 43277000 |
| Monday, January 1, 2018 | 22502922 | 48645000 |
| Tuesday, January 1, 2019 | 25910757 | 52934000 |
| Wednesday, January 1, 2020 | 35050817 | 61349000 |
| Friday, January 1, 2021 | 42896889 | 127125000 |
| Saturday, January 1, 2022 | 52458024 | 136106000 |
| Sunday, January 1, 2023 | 59020000 | 133175999 |
In the ever-evolving landscape of the biotechnology and pharmaceutical sectors, understanding the financial health of companies is crucial. Selling, General, and Administrative (SG&A) expenses are a key indicator of operational efficiency. Over the past decade, ADMA Biologics, Inc. and HUTCHMED (China) Limited have shown distinct trends in their SG&A expenses.
From 2014 to 2023, ADMA Biologics, Inc. saw a steady increase in SG&A costs, rising from approximately $4.8 million to nearly $59 million, marking a growth of over 1,100%. In contrast, HUTCHMED (China) Limited's expenses surged from $26.7 million to $133 million, a 400% increase. This stark difference highlights the varying strategies and market conditions faced by these companies.
Such insights are invaluable for investors and stakeholders aiming to make informed decisions in the competitive biotech industry.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and HUTCHMED (China) Limited
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Summit Therapeutics Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Exelixis, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Axsome Therapeutics, Inc. vs ADMA Biologics, Inc.
ADMA Biologics, Inc. or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Mesoblast Limited
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for HUTCHMED (China) Limited and Soleno Therapeutics, Inc.
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.